NEWS
Friday, July 17, 2009               HOME      ABOUT US     SUBSCRIBE     MEMBERS     CONTACT US  
ARCHIVES
Read Past Issues
NEWS
National
Metro
Africa
World
Business
OPINION
Editorial
Columnists
Contributors
Letters
Cartoons
Discussions
Outlook
SPORTS
Home
Abroad
Golf Weekly
Results
FEATURES
Focus
Policy & Politics
Arts
Media
Science
Natural Health
Law
Education
Weekend
Friday Review
Executive Briefs
Fashion
Food & Drink
Auto Wheels
Friday Worship
Saturday Magazine
Sunday Magazine
Ibru Ecumenical Centre
Agro Care
BUSINESS SERVICES
Property
Appointments
Money Watch
Market Report
Capital Market
Business Travels
Maritime Watch
Industry Watch
Energy Report
Insurance
Compulife
 

Friday, July 17, 2009              

Science uncovers genetic secrets of killer parasites

ANOTHER major victory has been recorded in man's battle against diseases with the decoding of the genetic blueprint of two parasitic flatworms said to be responsible for thousands of deaths globally.

The worms, Schistosoma mansoni and Schistosoma japonicum, are the major cause of the debilitating disease schistosomiasis, otherwise known as Bilharzia.

Scientists, according to the international study published in the journal, Mature, have already uncovered targets for new treatments for the disease, which causes fever and fatigue.

Schistosomiasis cases top 200 million every year, with 20 million people seriously disabled by severe anaemia, chronic diarrhoea, internal bleeding and organ damage caused by the worms and their eggs, or the immune system reactions they provoke.

In sub-Saharan Africa alone, the disease is said to have killed no fewer than 280,000 people yearly.

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said: "Chronic infection with Schistosoma parasites makes life miserable for millions of people in tropical countries around the globe and can lead to death."

"New drugs and other interventions are badly needed to reduce the impact of a disease that lowers quality of life and slows economic development", he added.

Since the 1980s, a cheap drug, praziquantel has been widely distributed to areas where the disease is common.

Although the drug is effective, experts claim that it does not prevent a person becoming re-infected. There is also a risk that the parasites will become resistant to it.

Developing new drug targets are generally seen as a major breakthrough.

Researchers working on the genetic blueprint of S. masoni, the most widespread of the schistosomiasis parasites, found that it was made up of 11,809 genes - about 10 times the size of the malaria parasite genome.

In particular, they identified a large number of genes which produce enzymes that break down proteins, giving the parasite its ability to bore through tissue.

Subsequent analysis revealed 120 enzymes that could potentially be targeted with drugs to disrupt the worm's metabolism.

The researchers also identified 66 drugs already in the market, which might also be effective against schistosomiasis.

The analysis also found that S. mansoni lacks a key enzyme needed to make essential fats, and must rely on its host to provide these - revealing a potential Achilles' heel that could be exploited for drug development.

Dr. Matthew Berriman of the Wellcome Trust Sanger Institute, said: "This genome sequence catapults schistosomiasis research into a new era."

"It provides a foundation for understanding aspects of the parasite's complex biology as well as a vehicle to immediately identify new targets for drug treatment", he stated.

Fellow researcher, Dr. Najib El-Sayed, of the University of Maryland, said: "The genome sequence has given us, for the first time, a comprehensive view of the engines that drive the parasite, the strategies that allow it to survive in us, its human host.

"It is a catalogue of opportunities."

In a separate study, scientists discovered that S. japonicum, which is largely confined to Asia, had even more genes.

 
 

© 2003 - 2009 @ Guardian Newspapers Limited (All Rights Reserved).
 Powered by FirstEntSol LTD®